Brief: Ironwood Presents New Data On Potential Of Linaclotide For Functional Constipation In
08/05/2023 12:55
May 8 (Reuters) - Ironwood Pharmaceuticals Inc IRWD.O :
* IRONWOOD PRESENTS NEW DATA ON POTENTIAL OF LINACLOTIDE FOR
FUNCTIONAL CONSTIPATION IN CHILDREN AND ADOLESCENTS AGES 6-17
YEARS-OLD AT DIGESTIVE DISEASE WEEK® 2023
* IRONWOOD - IN PIVOTAL STUDY, LINACLOTIDE SHOWED
STATISTICALLY
SIGNIFICANT, CLINICALLY MEANINGFUL IMPROVEMENT VERSUS PLACEBO IN
12-WEEK SBM FREQUENCY RATE
Source text for Eikon: ID:nBw8HrTfLa
Further company coverage: IRWD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ironwood Pharmaceuticals
See all newsBrief: Ironwood Pharmaceuticals Appoints Tammi Gaskins As Chief Executive Officer
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ironwood Q2 revenue rises 33%
Brief: Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026
Brief: FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation